Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma

Zhongqing Chen | Ying Wang | Min Fang

Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China

Correspondence
Zhongqing Chen, Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of China. Email: chenzhongqing@gxmu.edu.cn

Funding information
This work was supported by The National Natural Science Foundation of China (No. 81760530 to Min Fang).

Abstract

Background: The study of tumor markers (TM) in pleural effusion (PE) was not extensive.

Methods: TM in PE and serum were analyzed to determine whether TM was expressed in intrathoracic and extrathoracic tissues. To further verify the correlations between serum TM and tumor size, TNM stage of lung adenocarcinoma.

Results: Serum AFP was not correlated with tumor size, T stage, N stage, and M stage (P > .05). Serum CEA, serum CA125, serum CA15-3 were positively correlated with tumor size, T stage, N stage, M stage (P < .05). Serum CA19-9 was not significantly correlated with tumor size and T stage (P > .05), but was positively correlated with N stage and M stage (P < .05). The levels of PE CEA, PE CA125, PE CA15-3 were higher than those of serum CEA, serum CA125, serum CA15-3 (all P < .05). The level of PE AFP was lower than that of serum AFP (P < .05). The level of PE CA19-9 was not significantly different from that of serum CA19-9 (P > .05). The positive rates of PE CEA and PE CA125 were higher than those of serum CEA and serum CA125 (P < .05). The positive rates of PE AFP, PE CA15-3, PE CA19-9 were not significantly different from those of serum AFP, serum CA15-3, serum CA19-9 (P > .05). PE CEA, PE CA125, PE CA15-3 were moderately positively correlated with serum CEA, serum CA125, serum CA15-3, respectively (r = 0.597; r = 0.46; r = 0.583, all P < .05). However, PE AFP and PE CA19-9 were very strongly positively correlated with serum AFP and serum CA19-9, respectively (r = 0.888; r = 0.874, all P < .05).

Conclusion: The expression characteristics of TM in PE and serum supported the correlations between serum TM and tumor size, TNM stage of lung adenocarcinoma.

Keywords
lung adenocarcinoma, pleural effusion, serum, tumor marker
Pleural effusion (PE) was a blood filtrate. The pathogenesis of PE was tumor invading the pleura (parietal pleura and visceral pleura), or inflammation invading the pleura. Both of these conditions can affect the production of PE by parietal pleura or the absorption of PE by visceral pleura, resulting in increased PE. The formation mechanism of PE in lung cancer may be both. PE was more common in patients with advanced lung cancer, and the formation of PE often predicted a worsening condition for lung cancer patients. However, the underlying mechanisms were still under study.2-5

The expression products of lung tumors first entered PE. PE was diluted after entering the blood. Therefore, the expression products of lung tumors first appeared in PE, followed by blood. Blood and PE were in circulation. Similarly, the expression products from extrathoracic tissues first entered the blood, followed by PE. It was assumed that a certain TM was expressed only in the primary tissue of lung adenocarcinoma, but not in any metastatic tissues. The level and positive rate of this TM in PE was significantly higher than that in serum.6-11 Since the TM in blood was only derived from PE, the correlation between PE TM and serum TM was high.12 The amount of blood in human body was much higher than the amount of PE. A TM expressed only in extrathoracic tissue was circulated from the blood into the PE, there may be no significant difference in the level and positive rate of PE TM and serum TM. However, the correlation between PE TM and serum TM was still high. When a TM was expressed in both intrathoracic and extrathoracic tissues, the correlation between PE TM and serum TM was low.

In our previous study,13 serum CEA, serum CA125, serum CA15-3 were positively correlated with T stage, N stage, and M stage of lung adenocarcinoma. Serum CA19-9 was positively correlated with N stage and M stage of lung adenocarcinoma. The levels of serum TM may be influenced by tumor size, T stage, N stage, M stage, and other factors, so, the correlation coefficients were low. The results may be biased. To further verify the correlations between serum TM and tumor size, TNM stage of lung adenocarcinoma, we introduced PE for lung adenocarcinoma. Since PE tended to occur in advanced patients, the number of cases was small and PE rarely tested TM items. In addition, these patients had been treated with anti-tumor therapy, the correlations between TM and TNM stage were inaccurate. We analyzed the expression characteristics of TM in primary and metastatic tissues by comparing PE TM with serum TM. In this study, the first part would detail the correlations between serum CEA, serum AFP, serum CA125, serum CA15-3, serum CA19-9 and tumor size, TNM stage of lung adenocarcinoma. Tumor size and T stage represented primary tissue. N stage and M stage represented metastatic tissue. The second part would analyze serum TM and PE TM of lung adenocarcinoma. The two parts were mutually verified to further clarify the expression characteristics of TM in primary and metastatic tissues of lung adenocarcinoma.

2 | MATERIALS AND METHODS

2.1 | Patient information

This study was approved by the ethics committee of Guangxi Medical University Cancer Hospital with an Ethics approval number of LW2018011. This was a retrospective study that reviewed patients’ TM indicators. The patients in this study consisted of two parts. The first part were 335 cases of lung adenocarcinoma patients, which were hospitalized from October 2014 to August 2017. Included patients were those who met the following criteria: (a) The pathological diagnosis was lung adenocarcinoma; (b) No antineoplastic treatment; (c) Blood samples were collected on the second day of admission to test TM; (d) There were definite tumor size and TNM stage; (e) No other malignant tumors. The second part consisted of 84 cases of lung adenocarcinoma patients who were hospitalized from October 2015 to July 2018. Included patients were those who met the following criteria: (a) The pathological diagnosis was lung adenocarcinoma; (b) PE and serum were drawn on the same day to test TM; (c) No other malignant tumors; (d) PE came from the side of lung adenocarcinoma. All cases were staged according to the 2009 seventh edition14-16 and 2017 eighth edition17-19 of the tumor-nodes-metastasis (TNM) classification for lung cancer. Complete and detailed information was available for all cases.

2.2 | Tumor marker assay

The tests were completed on the day of blood drawn and PE drawn to avoid attenuation. All assays were performed according to instrument and reagent specifications. CEA, AFP, CA125, CA15-3, and CA19-9 were measured using ARCHITECTi2000SR automatic electrochemical luminescence instrument and matching reagents (Abbott Laboratories, Chicago). TM levels above the following values were considered abnormal: CEA, 5ng/ml; AFP 30ng/ml; CA125, 35ng/ml; CA15-3, 30ng/ml; CA19-9, 37ng/ml.

2.3 | CT scanning

Chest CT scans were performed using a Siemens somatom sensation 64-slice CT or a GE Discovery CT 750 HD. Scanning scheme: Ask the patients to hold their breath for a scan after inhaling. Using CARE DOSE technology, 120 kV,
pitch 1.000, layer thickness 5 mm; lung window (window width 1500 HU, window position −450 HU), mediastinum window (window width 400 HU, window position 40 HU), layer thickness 1 mm, interval 1 mm. Films were read by two experienced radiologists.

2.4 Statistical methods

Data were statistically analyzed using IBM SPSS21.0 software. The significance level was $P < .05$ (two tailed). Based on the normality test (skew and kurtosis coefficients), TM levels did not obey normal distribution. The levels between groups were compared by nonparametric rank sum test, Mann-Whitney U test. The positive rates between groups were compared by Chi-square test ($\chi^2$). The correlation was analyzed by Kendall's tau-b correlation analysis. The correlation coefficient grading: 0.8-1.0 Very strong correlation, 0.6-0.8 strong correlation, 0.4-0.6 moderate correlation, 0.2-0.4 weak correlation, 0.0-0.2 very weak correlation or no correlation.

3 RESULTS

3.1 Patient population and characteristics

Table 1 showed the patient population and characteristics. Part 1 was the information of 335 cases of lung adenocarcinoma. They were all first diagnosed and had not been treated with any anti-tumor therapy, such as surgery, chemotherapy, radiotherapy, biological therapy, endocrine therapy, Chinese medicine treatment, hyperthermia, and radiofrequency ablation therapy. Since decreased TM levels in patients with effective treatment will affect the correlation analysis between TNM stage and TM levels. In this cohort, there were 205 males (61.2%) and 130 females (38.8%). The average age was 57 years (28-86 years old). The primary tumor size of the lungs was 0.8-13 cm. This part of the patients had detailed TNM stage data, T1 83 (24.8%), T2 157 (46.9%), T3 58 (17.3%), T4 37 (11%); N0 107 (31.9%), N1 41 (12.2%), N2 114 (34%), N3 73 (21.8%); M0 203 (60.6%), M1 132 (39.4%). Part 2 was the information of 84 cases of lung adenocarcinoma all in stage IV and had been treated with anti-tumor agents. In this cohort, there were 51 (60.7%) males and 33 females (39.3%). The average age was 56.6 years (30-75 years old). Some patients did not have detailed TNM stage data, T1 7 (8.3%), T2 10 (11.9%), T3 9 (10.7%), T4 36(42.9%), Tx 22 (26.2%); N0 5 (6%), N1 4 (4.8%), N2 22 (26.2%), N3 31 (36.9%), Nx 22 (26.2%); M1 84 (100%).

### Table 1 Characteristics of the study subjects

| Parameters          | Part 1 | Part 2 |
|---------------------|--------|--------|
|                     | No.    | %      | No.    | %      |
| Gender              |        |        |        |        |
| Male                | 205    | 61.2   | 51     | 60.7   |
| Female              | 130    | 38.8   | 33     | 39.3   |
| Age (year)          |        |        |        |        |
| Range               | 28-86  | 30-75  |        |        |
| Mean                | 57     | 56.6   |        |        |
| Tumor size (cm)     | 0.8-13 | —      |        |        |
| T stage             |        |        |        |        |
| T1                  | 83     | 24.8   | 7      | 8.3    |
| T2                  | 157    | 46.9   | 10     | 11.9   |
| T3                  | 58     | 17.3   | 9      | 10.7   |
| T4                  | 37     | 11     | 36     | 42.9   |
| Tx                   | 0      | 0      | 22     | 26.2   |
| N stage             |        |        |        |        |
| N0                  | 107    | 31.9   | 5      | 6      |
| N1                  | 41     | 12.2   | 4      | 4.8    |
| N2                  | 114    | 34     | 22     | 26.2   |
| N3                  | 73     | 21.8   | 31     | 36.9   |
| Nx                   | 0      | 0      | 22     | 26.2   |
| M stage             |        |        |        |        |
| M0                  | 203    | 60.6   | 0      | 0      |
| M1                  | 132    | 39.4   | 84     | 100    |

3.2 Correlation between tumor size, TNM stage, and serum tumor markers levels in part 1

Table 2 showed the serum TM of 335 cases of lung adenocarcinoma. First, the minimum, maximum, median, positive rates of serum TM were analyzed, and then the correlations between serum TM and tumor size, TNM stage were analyzed. The lowest values of CEA, AFP, CA125, CA15-3, and CA19-9 were lower than the upper line of normal value. The highest values of CEA, AFP, CA125, CA15-3, and CA19-9 were higher than the upper line of normal value. The median of CEA was higher than the upper line of normal value, the median of AFP, CA125, CA15-3, and CA19-9 were lower than the upper line of normal value. The median of CEA was higher than the upper line of normal value, the median of AFP, CA125, CA15-3, and CA19-9 were lower than the upper line of normal value. The positive rates were ranked as CEA>CA125>CA15-3>CA19-9>AFP. CEA was positively correlated with tumor size, T stage, N stage, M stage ($r = 0.146; r = 0.218; r = 0.349; r = 0.358$, all $P < .05$). CA125 was positively correlated with tumor size, T stage, N
stage, M stage \((r = 0.219; r = 0.298; r = 0.398; r = 0.358, \text{all } P < .05)\). CA15-3 was positively correlated with tumor size, T stage, N stage, M stage \((r = 0.197; r = 0.254; r = 0.325; r = 0.282, \text{all } P < .05)\). CA19-9 was not significantly correlated with tumor size and T stage \((r = 0.063; r = 0.061, \text{all } P > .05)\). CA19-9 was positively correlated with N stage and M stage \((r = 0.118; r = 0.145, \text{all } P < .05)\). There were no correlations between AFP and tumor size, T stage, N stage, M stage \((r = -0.050; r = -0.052; r = -0.026; r = 0.068, \text{all } P > .05)\).

### Table 2

The range, median, positive rates, and correlation analysis of serum tumor markers and TNM stage of lung adenocarcinoma in part 1

| Parameters | CEA | AFP | CA125 | CA15-3 | CA19-9 |
|------------|-----|-----|-------|--------|--------|
| Range (ng/mL) | 0.65-1000 | 0.60-89.66 | 0.60-2103 | 5.24-300 | 0.23-1000 |
| Median (ng/mL) | 6.82 | 2.66 | 20.28 | 19.93 | 14.35 |
| Positive rate (%) | 62.4 | 2.1 | 36.7 | 28.4 | 21.5 |

| Correlation |
|-------------|
| Tumor size |
| \(r\) | .146 | -.050 | .219 | .197 | .063 |
| \(P\) | .000 | .173 | .000 | .000 | .087 |
| T stage |
| \(r\) | .218 | -.052 | .298 | .254 | .061 |
| \(P\) | .000 | .213 | .000 | .000 | .146 |
| N stage |
| \(r\) | .349 | -.026 | .398 | .325 | .118 |
| \(P\) | .000 | .534 | .000 | .000 | .004 |
| M stage |
| \(r\) | .358 | .068 | .358 | .282 | .145 |
| \(P\) | .000 | .127 | .000 | .000 | .001 |

### Table 3

Tumor markers levels in pleural effusion and serum of lung adenocarcinoma in part 2

Table 3 showed the PE TM and serum TM of 84 cases of lung adenocarcinoma. First, the minimum, maximum, median, positive rates of PE TM, and serum TM were analyzed, and then the correlations between serum TM and PE TM were analyzed.

In both PE and serum, the lowest values of CEA, AFP, CA125, CA15-3, and CA19-9 were lower than the upper

### 3.3 Correlation between PE tumor markers levels and serum tumor markers levels in part 2

| Parameters | CEA | AFP | CA125 | CA15-3 | CA19-9 |
|------------|-----|-----|-------|--------|--------|
| Range (ng/mL) | 0.5-1500 | 0.53-8.61 | 5.6-5000 | 1.2-800 | 0-1200 |
| Median (ng/mL) | 100.00 | 1.57 | 600.00 | 64.23 | 13.60 |
| \(z\) | -4.397 | -6.986 | -7.735 | -2.000 | -0.814 |
| \(P\)-value | .000 | .000 | .000 | .045 | .416 |

| Positive rate |
|---------------|
| PE (%) | 88.1 | 0.0 | 95.2 | 66.7 | 34.5 |
| Serum (%) | 72.6 | 0.0 | 85.7 | 60.7 | 32.1 |
| \(\chi^2\) | 6.373 | — | 4.421 | 0.643 | 0.107 |
| \(P\)-value | .012 | — | .035 | .422 | .743 |

| Correlation |
|-------------|
| \(r\) | 0.597 | 0.888 | 0.460 | 0.583 | 0.874 |
| \(P\)-value | .002 | .000 | .024 | .003 | .000 |
line of normal value, the maximum values of CEA, CA125, CA15-3, and CA19-9 were higher than the upper line of normal value, the maximum value of AFP was lower than the upper line of normal value. The median of CEA, CA125, and CA15-3 were higher than the upper line of normal value, the median of AFP and CA19-9 were lower than the upper line of normal value. The levels of PE CEA, PE CA125, and PE CA15-3 were higher than those of serum CEA, serum CA125, serum CA15-3, respectively ($z = -4.397$; $z = -7.735$; $z = -2.000$, all $P < .05$). The level of PE AFP was lower than that of serum AFP ($z = -6.986$, $P < .05$). The level of PE CA19-9 was not significantly different from that of serum CA19-9 ($z = -0.814$, $P > .05$).

The positive rates were ranked as CA125>CEA>CA15-3>CA19-9>AFP in both PE and serum. The positive rates of PE CEA and PE CA125 were higher than those of serum CEA, serum CA125, respectively. The positive rates of PE AFP, PE CA15-3, and PE CA19-9 were not significantly different from those of serum AFP, serum CA15-3, serum CA19-9, respectively ($z = 0.000$; $z = 0.643$; $z = 0.107$, all $P > .05$).

PE CEA, PE CA125, PE CA15-3 were moderately positively correlated with serum CEA, serum CA125, serum CA15-3, respectively ($r = 0.597$; $r = 0.46$; $r = 0.583$, all $P < .05$). PE AFP, PE CA19-9 were very strongly positively correlated with serum AFP and serum CA19-9, respectively ($r = 0.888$; $r = 0.874$, all $P < .05$). Figure 1.

4 DISCUSSION

Exclude patients without tumor size data, only 335 cases of lung adenocarcinoma were studied in part 1. It was noteworthy that the conclusions were consistent with the previous 424 cases of lung adenocarcinoma.13 Tumor size largely determines T stage. The correlations between TM levels and tumor size were consistent with the correlations between TM levels and T stage. The production of PE may be due to inflammation or tumors. Normal cells and certain benign diseases can only synthesize or secrete CEA in small amounts.20 CA125 levels were significantly higher in malignant PE than in benign PE.21,22 The positive rate of PE CEA was 88.1%, the positive rate of PE CA125 was 95.2%. The causes of PE and elevated PE TM were still by tumor. We compared serum TM and PE TM in part 2. The positive rates were consistently ranked as CA125>CEA>CA15-3>CA19-9>AFP in both PE and serum. PE TM was moderately and above positively correlated with serum TM, PE CA19-9 and PE AFP were highly correlated with serum CA19-9 and serum AFP, suggesting that CA19-9 and AFP were expressed in intrathoracic or extrathoracic tissues. PE CEA, PE CA125, PE CA15-3 were positively correlated with serum CEA, serum CA125, serum CA15-3, suggesting that CEA, CA125, CA15-3 were expressed in both intrathoracic and extrathoracic tissues.

AFP was a TM of hepatocellular carcinoma and was irrelevant to lung adenocarcinoma.23 In part 2, the positive rates of PE AFP and serum AFP were all 0%. PE AFP level was significantly lower than that of serum AFP. There was a very strong correlation between PE AFP and serum AFP. AFP may be only expressed in extrathoracic tissues, which supported there were no significant correlations between serum AFP level and tumor size, T stage, N stage, M stage in part 1.

CEA was the antibody to be tumor-cell specific. CEA was widely recognized as a TM with high sensitivity and specificity for lung cancer,24-26 especially lung adenocarcinoma.21,27-29 CEA also has a good performance in the identification of benign and malignant PE.30,31 PE CA125 of carcinomatous pleuritis was produced by not only carcinoma cells but also activated mesothelial cells.32 In part 2, the expression of CEA and CA125 in serum and PE were similar. The median and positive rates of PE CEA (100,88.1%), PE CA125 (600,95.2%), serum CEA (18.95,72.6%), serum CA125 (98.05,85.7%) were at high levels. The levels and positive rates of PE CEA and PE CA125 were significantly higher than those of serum CEA and serum CA125, respectively. Moderate positive correlations were observed between PE CEA, PE CA125 and serum CEA, serum CA125, similar to another report.12 CEA and CA125 were probably expressed in both intrathoracic and extrathoracic tissues, and the expression levels in intrathoracic tissues were higher than that in extrathoracic tissues. So, in part 1, serum CEA and serum CA125 were positively correlated with tumor size, T stage, N stage, M stage.

CA15-3 was commonly used in diagnosis and prognosis of breast cancer.33 High PE CA15-3 levels indicated inflammatory disease or malignant tumor.34 Higher PE CA15-3 levels were observed in malignant PE with positive cytology.35 PE CA15-3 showed significantly high specificity in malignant PE.36-39 In part 2, the level of PE CA15-3 was higher than that of serum CA15-3, the positive rate of PE CA15-3 was not significantly different from serum CA15-3. PE CA15-3 were moderately positively correlated with serum CA15-3. The positive rates of PE CA15-3 and serum CA15-3 (66.7%, 60.7%) were lower than those of CEA (88.1%, 72.6%) and CA125 (95.2%, 85.7%). CA15-3 may be expressed in both intrathoracic and extrathoracic tissues, but was less expressed than CEA and CA125. So, in part 1, serum CA15-3 was significantly positively correlated with tumor size, T stage, N stage, M stage.

Some studies suggested that the level of PE CA19-9 in malignant PE and benign PE were similar,6 CA19-9 was significantly increased in lung adenocarcinoma-associated malignant PE compared to benign PE,40,41 PE CA19-9 was
hyposensitive to lung adenocarcinoma. While other studies reported PE CA19-9 and PE CA125 in bronchoalveolar lavage fluid of lung cancer were more useful markers than PE CA15-3. So, CA19-9 was controversial in identifying benign and malignant PE. In part 2, PE CA19-9 was strongly positively correlated with serum CA19-9, indicating that CA19-9 was only expressed in intrathoracic or extrathoracic tissues. The blood volume of human body was much higher than the volume of PE in the thoracic cavity. When CA19-9 enters PE from the blood, the concentration of CA19-9 decreased insignificantly. The level and positive rate of PE CA19-9 were not significantly different.
from those of serum CA19-9. CA19-9 maybe expressed in extrathoracic tissues, may be associated with the metastasis of lung adenocarcinoma. So, in part 1, serum CA19-9 was not significantly correlated with tumor size and T stage, but serum CA19-9 was significantly positively correlated with N stage and M stage.

5 | CONCLUSIONS

The expression characteristics of TM in PE and serum supported the correlations between serum TM and tumor size, TNM stage of lung adenocarcinoma. Serum CEA, serum CA125, and serum CA15-3 were positively correlated with tumor size, T stage, N stage, M stage of lung adenocarcinoma. Serum CA19-9 was positively correlated with N stage, and M stage of lung adenocarcinoma, but not correlated with tumor size and T stage. Serum AFP was not correlated with tumor size, T stage, N stage, and M stage of lung adenocarcinoma.

ACKNOWLEDGMENTS

The authors thank Dr Jie Ma for her contribution in imaging, and Dr Liufu Su's contribution in pathophysiology.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

ZQC, YW and MF conceived and designed the project. ZQC and YW collected the clinical specimens and data. ZQC, YW and MF performed the statistical analysis and wrote the manuscript. ZQC, YW and MF contributed to the writing and critical reading of the paper. All authors read and approved the final manuscript.

ETHICAL APPROVAL

This study was approved by the ethics committee of the Guangxi Medical University Cancer Hospital with an ethics approval number of LW2018011.

CONSENT FOR PUBLICATION

Not applicable.

DATA AVAILABILITY STATEMENT

The datasets used during the current study were available from the corresponding author on reasonable request.

ORCID

Zhongqing Chen https://orcid.org/0000-0001-8062-7011

REFERENCES

1. Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation-fantasy or future? J Thorac Dis. 2015;7(6):1009-1020.
2. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(Suppl 1):45-50.
3. Moschos C, Psallis I, Kollintza A, et al. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia. 2009;11(3):298-304.
4. Giannou AD, Marazioti A, Spella M, et al. Mast cells mediate malignant pleural effusion formation. J Clin Investig. 2015;125(6):2317-2334.
5. Agalioti T, Giannou AD, Krontira AC, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017;8:15205.
6. Ustun H, Borazan A, Bilgici N, Yilmaz A. Diagnostic value of tumoural markers in pleural effusions. Int J Clin Pract. 2004;58(1):22-25.
7. Niwa Y, Shimokata K. Diagnostic significance of cancer antigen 125, pancreatic oncofetal antigen, and carcinoembryonic antigen in malignant and tuberculous pleural effusions. Jpn J Clin Oncol. 1986;16(1):3-8.
8. Korczynski P, Krenke R, Safianowska A, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res. 2009;14(Suppl 4):128-133.
9. Gu Y, Zhai K, Shi HZ. Clinical value of tumor markers for determining cause of pleural effusion. Chin Med J. 2016;129(3):253-258.
10. Huang F, Wang XL, Yang L, Yin BX, Geng Y, Li TT. Clinical value of combined determination of serum and pleural effusion level of CEA, CYFRA21-1, TPS in the diagnosis of lung cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24(4):370-372.
11. Trapé J, Sant F, Franquesa J, et al. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. Respir Res. 2017;18(1):103.
12. How SH, Liam CK, Jamalludin AR, Chin SP, Zal AB. Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia. 2006;61(5):558-563.
13. Chen ZQ, Huang LS, Zhu B. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers. 2018;2018:945123.
14. Travis WD, Giroux DJ, Chansky K, et al. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thoracic Oncol. 2008;3(11):1213-1223.
15. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thoracic Oncol. 2007;2(8):694-705.
16. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thoracic Oncol. 2007;2(8):706-714.
17. Asamura H, Chansky K, Crowley J, et al. The International Association for the study of lung cancer lung cancer staging project. J Thoracic Oncol. 2015;10(12):1675-1684.
18. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thoracic Oncol. 2015;10(7):990-1003.
19. Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC lung cancer staging project. J Thoracic Oncol. 2015;10(11):1515-1522.
20. Neubauer A, Thalmann U, Musch R, Grosser H, Loddenkemper R, Huhn D. Prospective comparison of the diagnostic value of cytology and immunocytology in pleural effusion studied by thoracoscopy and biopsy. Klin Wochenschr. 1987;65(9):400-406.
21. Jibiki K, Abe Y, Takeda M, et al. Clinical evaluation of various tumor markers in pleural effusion and in the serum. Gan No Rinsho. 1989;35(9):991-998.
22. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21–1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell carcinoma antigen in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86(8):1488-1495.
23. Wang XF, Wu YH, Wang MS, Wang YS, CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev. 2014;15(1):363-368.
24. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13(4):518-527.
25. Tozzoli R, Basso SM, D’Aurizio F, Metus P, Lumachi F. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: a prospective study and literature review. Clin Biochem. 2016;49(16-17):1227-1231.
26. Tada A, Kawai H, Matsumoto H, et al. Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy. Nihon Kokyuki Gakkai Zasshi. 2002;40(2):106-112.
27. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21–1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology. 2010;42(3):224-228.
28. Li H, Huang L, Tang H, Zhong N, He J. Pleural fluid carcinoembryonic antigen as a biomarker for the discrimination of tumor-related pleural effusion. Clin Respir J. 2017;11(6):881-886.
29. Yu YX, Tong ZH, Zhou XX, et al. Evaluation of the diagnosis value of carcinoembryonic antigen in malignant pleural effusion. Zhonghua Yi Xue Za Zhi. 2018;98(6):432-435.
30. Gu P, Huang G, Chen Y, Zhi C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21–1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21(6):398-405.
31. Hesdorffer C, Derman DP, Bezwoda WR. The value of pleural fluid carcinoembryonic antigen estimation in the diagnosis of malignant tumours of the pleural cavity. S Afr Med J. 1984;66(2):54-56.
32. Tomita Y. Clinical evaluation and tissue distribution of CA125 in patients with pleural effusion. Igaku Kenkyu. 1989;59(3):90-96.
33. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15–3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers. 2018;2018:9863092.
34. Topolcan O, Holubec L, Polivkova V, et al. Tumor markers in pleural effusions. Anticancer Res. 2007;27(4a):1921-1924.
35. Antonangelo L, Sales RK, Cora AP, Accinno MM, Teixeira LR, Vargas FS. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytolologic results. Curr Oncol. 2015;22(5):e3 36-e341.
36. Wu Q, Li M, Zhang S, Chen L, Gu X, Xu F. Clinical diagnostic utility of CA 15–3 for the diagnosis of malignant pleural effusion: a meta-analysis. Exp Ther Med. 2015;9(1):232-238.
37. Villena V, Lopez-Encuentra A, Echave-Sustaita J, Martin-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 72–4, carcinoembryonic antigen, CA 15–3, and CA 19–9 assay in pleural fluid. A study of 207 patients. Cancer. 1996;78(4):736-740.
38. Porcel JM, Civit C, Esquerra A, Salud A, Bielsa S. Utility of CEA and CA 15–3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: a single-center experience. Arch Bronconeumol. 2017;53(8):427-431.
39. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15–3, CA 19–9, CYFRA 21–1, NSE and TSA assay in pleural effusions. Lung Cancer. 2001;31(1):9-16.
40. Feng M, Zhu J, Liang L, et al. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. Int J Clin Oncol. 2017;22(2):283-290.
41. Asada K, Ogushi F, Tani K, et al. Measurement of CA19-9 in bronchial lavage fluid from patients with lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30(9):1682-1686.
42. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63(1):35-41.
43. Ghosh I, Bhattacharjee D, Das AK, Chakrabarti G, Dasgupta A, Dey SK. Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J Clin Biochem. 2013;28(1):24-29.

How to cite this article: Chen Z, Wang Y, Fang M. Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma. Cancer Med. 2020;9:1392–1399. https://doi.org/10.1002/cam4.2809